Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 840542, 26 pages
http://dx.doi.org/10.1155/2015/840542
Review Article

Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma

1Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung 80284, Taiwan
2Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Section 2, Cheng-Kung Road, Neihu, Taipei 114, Taiwan
3Department of Pathology, Kaohsiung Armed Forces General Hospital, Kaohsiung 80284, Taiwan
4Department of General Surgery, Kaohsiung Armed Forces General Hospital, Kaohsiung 80284, Taiwan

Received 2 September 2015; Accepted 19 October 2015

Academic Editor: Javier G. Gallego

Copyright © 2015 Chen-Yi Liao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. W. Burak and M. Sherman, “Hepatocellular carcinoma: consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting,” Canadian Journal of Gastroenterology & Hepatology, vol. 29, no. 4, pp. 178–184, 2015. View at Google Scholar
  2. A. Schlachterman, W. W. Craft Jr., E. Hilgenfeldt, A. Mitra, and R. Cabrera, “Current and future treatments for hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 21, no. 28, pp. 8478–8491, 2015. View at Publisher · View at Google Scholar
  3. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Srivatanakul, H. Sriplung, and S. Deerasamee, “Epidemiology of liver cancer: an overview,” Asian Pacific Journal of Cancer Prevention, vol. 5, no. 2, pp. 118–125, 2004. View at Google Scholar
  5. F. X. Bosch, J. Ribes, M. Díaz, and J. Ribes, “Primary liver cancer: worldwide incidence and trends,” Gastroenterology, vol. 127, no. 5, supplement 1, pp. S5–S16, 2004. View at Google Scholar
  6. M. A. Feitelson, B. Sun, N. L. Satiroglu Tufan, J. Liu, J. Pan, and Z. Lian, “Genetic mechanisms of hepatocarcinogenesis,” Oncogene, vol. 21, no. 16, pp. 2593–2604, 2002. View at Publisher · View at Google Scholar
  7. H. O. El Mesallamy, N. S. Metwally, M. S. Soliman, K. A. Ahmed, and M. M. El Mesallamy, “The chemopreventive effect of Ginkgo biloba and Silybum marianum extracts on hepatocarcinogenesis in rats,” Cancer Cell International, vol. 11, no. 1, article 38, 2011. View at Publisher · View at Google Scholar
  8. S. Udali, P. Guarini, A. Ruzzenente et al., “DNA methylation and gene expression profiles show novel regulatory pathways in hepatocellular carcinoma,” Clinical Epigenetics, vol. 7, article 43, 2015. View at Publisher · View at Google Scholar
  9. H. V. Tong, C. T. Bock, and T. P. Velavan, “Genetic insights on host and hepatitis B virus in liver diseases,” Mutation Research/Reviews in Mutation Research, vol. 762, pp. 65–75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M.-A. Buendia and C. Neuveut, “Hepatocellular carcinoma,” Cold Spring Harbor Perspectives in Medicine, vol. 5, no. 2, Article ID a021444, 2015. View at Publisher · View at Google Scholar
  11. M. C. Wallace, D. Preen, G. P. Jeffrey, and L. A. Adams, “The evolving epidemiology of hepatocellular carcinoma: a global perspective,” Expert Review of Gastroenterology & Hepatology, vol. 9, no. 6, pp. 765–779, 2015. View at Publisher · View at Google Scholar
  12. S. Roayaie, I. N. Blume, S. N. Thung et al., “A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma,” Gastroenterology, vol. 137, no. 3, pp. 850–855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. Y.-C. Shen, Z.-Z. Lin, C.-H. Hsu, C. Hsu, Y.-Y. Shao, and A.-L. Cheng, “Clinical trials in hepatocellular carcinoma: an update,” Liver Cancer, vol. 2, no. 3-4, pp. 345–364, 2013. View at Publisher · View at Google Scholar
  14. J. F. Xia, J. J. Gao, Y. Inagaki, N. Kokudo, M. Nakata, and W. Tang, “Flavonoids as potential anti-hepatocellular carcinoma agents: recent approaches using HepG2 cell line,” Drug Discoveries & Therapeutics, vol. 7, no. 1, pp. 1–8, 2013. View at Publisher · View at Google Scholar
  15. R. Kaufmann, P. Henklein, P. Henklein, and U. Settmacher, “Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation,” Oncology Reports, vol. 21, no. 5, pp. 1261–1267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. X.-L. Chen, Q. Wang, L.-Q. Cao et al., “Epigallocatechin-3-gallate induces apoptosis in human hepatocellular carcinoma cells,” Zhonghua Yi Xue Za Zhi, vol. 88, no. 36, pp. 2524–2528, 2008. View at Google Scholar · View at Scopus
  17. X. Shan, Y. Li, X. Meng, P. Wang, P. Jiang, and Q. Feng, “Curcumin and (−)-epigallocatechin-3-gallate attenuate acrylamide-induced proliferation in HepG2 cells,” Food and Chemical Toxicology, vol. 66, pp. 194–202, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Zhang, L. Owusu, W. Duan et al., “Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells,” International Journal of Molecular Medicine, vol. 32, no. 4, pp. 959–964, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Lu, H.-M. Liu, and W.-X. Tang, “Effect of epigallocatechin-3-gallate on the invasiveness of hepatocarcinoma cells in vitro,” Zhonghua Gan Zang Bing Za Zhi, vol. 15, no. 11, pp. 825–827, 2007. View at Google Scholar · View at Scopus
  20. Y.-F. Wang, T. Li, Z.-H. Tang et al., “Baicalein triggers autophagy and inhibits the protein kinase B/mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells,” Phytotherapy Research, vol. 29, no. 5, pp. 674–679, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-H. Zheng, L.-H. Yin, T. H. M. Grahn, A.-F. Ye, Y.-R. Zhao, and Q.-Y. Zhang, “Anticancer effects of baicalein on hepatocellular carcinoma cells,” Phytotherapy Research, vol. 28, no. 9, pp. 1342–1348, 2014. View at Publisher · View at Google Scholar
  22. W. Dai, F. Wang, L. He et al., “Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor NFAT1,” Molecular Carcinogenesis, vol. 54, no. 4, pp. 301–311, 2015. View at Publisher · View at Google Scholar
  23. M. Xu, N. Lu, Z. Sun et al., “Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells,” Toxicology Letters, vol. 212, no. 2, pp. 113–125, 2012. View at Publisher · View at Google Scholar
  24. M. Zou, N. Lu, C. Hu et al., “Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling,” Cellular Signalling, vol. 24, no. 8, pp. 1722–1732, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Wang, J. Wu, B. Lin et al., “Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway,” Toxicology, vol. 326, pp. 9–17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Kiyono, H. I. Suzuki, H. Matsuyama et al., “Autophagy is activated by TGF-β and potentiates TGF-β-mediated growth inhibition in human hepatocellular carcinoma cells,” Cancer Research, vol. 69, no. 23, pp. 8844–8852, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. R. H. Lee, J. H. Cho, Y.-J. Jeon et al., “Quercetin induces antiproliferative activity against human hepatocellular carcinoma (HepG2) cells by suppressing specificity protein 1 (Sp1),” Drug Development Research, vol. 76, no. 1, pp. 9–16, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Li, S. Duan, H. Jia, C. Bai, L. Zhang, and Z. Wang, “Flavonoids from tartary buckwheat induce G2/M cell cycle arrest and apoptosis in human hepatoma HepG2 cells,” Acta Biochimica et Biophysica Sinica, vol. 46, no. 6, pp. 460–470, 2014. View at Publisher · View at Google Scholar
  29. S. Zhang, Y. Yang, Z. Liang et al., “Silybin-mediated inhibition of notch signaling exerts antitumor activity in human hepatocellular carcinoma cells,” PLoS ONE, vol. 8, no. 12, Article ID e83699, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. H. R. Gu, S. C. Park, S. J. Choi et al., “Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells,” Clinical and Molecular Hepatology, vol. 21, no. 1, pp. 49–59, 2015. View at Publisher · View at Google Scholar
  31. J. P. Rigalli, N. Ciriaci, A. Arias et al., “Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity,” PLoS ONE, vol. 10, no. 3, Article ID e0119502, 2015. View at Publisher · View at Google Scholar
  32. M. Shimizu, Y. Shirakami, H. Sakai et al., “EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells,” Cancer letters, vol. 262, no. 1, pp. 10–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Shen, Y. Zhang, Y. Feng et al., “Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes S phase arrest in hepatocellular carcinoma by suppressing the AKT pathway,” International Journal of Oncology, vol. 44, no. 3, pp. 791–796, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. W. P. Tsang and T. T. Kwok, “Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells,” The Journal of Nutritional Biochemistry, vol. 21, no. 2, pp. 140–146, 2010. View at Publisher · View at Google Scholar
  35. J.-L. Tong, F. Nie, Z.-H. Ran et al., “Epigallocatechin gallate induces apoptosis in human hepatocellular carcinoma HepG2 cells via TGF/Smad signaling pathway,” Zhonghua Zhong Liu Za Zhi, vol. 31, no. 9, pp. 646–650, 2009. View at Google Scholar · View at Scopus
  36. M. M. Darweish, A. Abbas, M. A. Ebrahim, and M. M. H. Al-Gayyar, “Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway,” Journal of Pharmacy and Pharmacology, vol. 66, no. 7, pp. 1032–1045, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Chen, S. Zhang, Y. Ji et al., “Baicalein inhibits the invasion and metastatic capabilities of hepatocellular carcinoma cells via down-regulation of the ERK pathway,” PLoS ONE, vol. 8, no. 9, Article ID e72927, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. W.-H. Chang, C.-H. Chen, R.-J. Gau et al., “Effect of baicalein on apoptosis of the human Hep G2 cell line was induced by mitochondrial dysfunction,” Planta Medica, vol. 68, no. 4, pp. 302–306, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. C.-Y. Jin, C. Park, G.-Y. Kim, S.-J. Lee, W.-J. Kim, and Y. H. Choi, “Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells,” Chemico-Biological Interactions, vol. 180, no. 2, pp. 143–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Liu, R. Mu, F.-F. Nie et al., “MAC related mitochondrial pathway in oroxylin A induces apoptosis in human hepatocellular carcinoma HepG2 cells,” Cancer Letters, vol. 284, no. 2, pp. 198–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. H.-T. Zhang, J. Wu, M. Wen, L.-J. Su, and H. Luo, “Galangin induces apoptosis in hepatocellular carcinoma cells through the caspase 8/t-Bid mitochondrial pathway,” Journal of Asian Natural Products Research, vol. 14, no. 7, pp. 626–633, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. A. B. Granado-Serrano, M. A. Martín, L. Bravo, L. Goya, and S. Ramos, “Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2),” Journal of Nutrition, vol. 136, no. 11, pp. 2715–2721, 2006. View at Google Scholar · View at Scopus
  43. M. Momeny, M. R. Khorramizadeh, S. H. Ghaffari et al., “Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation,” European Journal of Pharmacology, vol. 591, no. 1–3, pp. 13–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. S. Yu and E. B. Keeffe, “Management of hepatocellular carcinoma,” Reviews in Gastroenterological Disorders, vol. 3, no. 1, pp. 8–24, 2003. View at Google Scholar · View at Scopus
  45. G. M. Cragg, P. G. Grothaus, and D. J. Newman, “Impact of natural products on developing new anti-cancer agents,” Chemical Reviews, vol. 109, no. 7, pp. 3012–3043, 2009. View at Publisher · View at Google Scholar
  46. Y.-L. Cheng, W.-L. Chang, S.-C. Lee et al., “Acetone extract of Angelica sinensis inhibits proliferation of human cancer cells via inducing cell cycle arrest and apoptosis,” Life Sciences, vol. 75, no. 13, pp. 1579–1594, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. J. N. Nwodo, A. Ibezim, C. V. Simoben, and F. Ntie-Kang, “Exploring cancer therapeutics with natural products from African medicinal plants, part II: alkaloids, terpenoids and flavonoids,” Anti-Cancer Agents in Medicinal Chemistry, vol. 16, no. 1, pp. 108–127, 2015. View at Publisher · View at Google Scholar
  48. A. Cassidy, G. Rogers, J. J. Peterson, J. T. Dwyer, H. Lin, and P. F. Jacques, “Higher dietary anthocyanin and flavonol intakes are associated with anti-inflammatory effects in a population of US adults,” The American Journal of Clinical Nutrition, vol. 102, no. 1, pp. 172–181, 2015. View at Publisher · View at Google Scholar
  49. M. M. de Jesús Romero-Prado, J. A. Curiel-Beltrán, M. V. Miramontes-Espino, E. G. Cardona-Muñoz, A. Rios-Arellano, and L.-B. Balam-Salazar, “Dietary flavonoids added to pharmacological antihypertensive therapy are effective in improving blood pressure,” Basic and Clinical Pharmacology and Toxicology, vol. 117, no. 1, pp. 57–64, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Chirumbolo, “Flavonoids in coronary heart disease,” Thrombosis Research, vol. 135, no. 5, pp. 1040–1041, 2015. View at Publisher · View at Google Scholar
  51. Z. Weng, A. B. Patel, S. Panagiotidou, and T. C. Theoharides, “The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells,” Journal of Allergy and Clinical Immunology, vol. 135, no. 4, pp. 1044–1052.e5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. N. F. M. Fozi, M. Mazlan, A. N. Shuid, and I. N. Mohamed, “Milk thistle: a future potential anti-osteoporotic and fracture healing agent,” Current Drug Targets, vol. 14, no. 14, pp. 1659–1666, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. W. Dong, X. Wei, F. Zhang et al., “A dual character of flavonoids in influenza A virus replication and spread through modulating cell-autonomous immunity by MAPK signaling pathways,” Scientific Reports, vol. 4, article 7237, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. X.-F. Yang, Y.-L. Wang, and W.-R. Xu, “Reviews on antiviral activity of chemical constituents from plants,” Zhongguo Zhongyao Zazhi, vol. 33, no. 1, pp. 100–104, 2008. View at Google Scholar · View at Scopus
  55. X. Song, Y. Chen, Y. Sun et al., “Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide,” Pharmacological Reports, vol. 64, no. 5, pp. 1189–1199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. C. Jung, M. E. Kim, J. H. Yoon et al., “Anti-inflammatory effects of galangin on lipopolysaccharide-activated macrophages via ERK and NF-κB pathway regulation,” Immunopharmacology and Immunotoxicology, vol. 36, no. 6, pp. 426–432, 2014. View at Publisher · View at Google Scholar
  57. S. Chirumbolo, “Quercetin as a potential anti-allergic drug: which perspectives?” Iranian Journal of Allergy, Asthma and Immunology, vol. 10, no. 2, pp. 139–140, 2011. View at Google Scholar
  58. S.-Y. Lyu, J.-Y. Rhim, and W.-B. Park, “Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro,” Archives of Pharmacal Research, vol. 28, no. 11, pp. 1293–1301, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. A. E. dos Santos, R. M. Kuster, K. A. Yamamoto et al., “Quercetin and quercetin 3-O-glycosides from Bauhinia longifolia (Bong.) Steud. show anti-Mayaro virus activity,” Parasites and Vectors, vol. 7, article 130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Horie, N. Hirabayashi, Y. Takahashi, Y. Miyauchi, H. Taguchi, and K. Takeishi, “Synergistic effect of green tea catechins on cell growth and apoptosis induction in gastric carcinoma cells,” Biological and Pharmaceutical Bulletin, vol. 28, no. 4, pp. 574–579, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. S. B. Lotito and B. Frei, “Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?” Free Radical Biology and Medicine, vol. 41, no. 12, pp. 1727–1746, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. F.-Y. Tang, N. Nguyen, and M. Meydani, “Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule,” International Journal of Cancer, vol. 106, no. 6, pp. 871–878, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Kojima-Yuasa, J. J. Hua, D. O. Kennedy, and I. Matsui-Yuasa, “Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors,” Life Sciences, vol. 73, no. 10, pp. 1299–1313, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Khan and H. Mukhtar, “Dietary agents for prevention and treatment of lung cancer,” Cancer Letters, vol. 359, no. 2, pp. 155–164, 2015. View at Publisher · View at Google Scholar
  65. A. Srinivasan, C. Thangavel, Y. Liu et al., “Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer,” Molecular Carcinogenesis, 2015. View at Publisher · View at Google Scholar
  66. J. L. Petrick, S. E. Steck, P. T. Bradshaw et al., “Dietary intake of flavonoids and oesophageal and gastric cancer: incidence and survival in the United States of America (USA),” British Journal of Cancer, vol. 112, no. 7, pp. 1291–1300, 2015. View at Publisher · View at Google Scholar
  67. R. Zamora-Ros, V. Fedirko, A. Trichopoulou et al., “Dietary flavonoid, lignan and antioxidant capacity and risk of hepatocellular carcinoma in the European prospective investigation into cancer and nutrition study,” International Journal of Cancer, vol. 133, no. 10, pp. 2429–2443, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Papaj, A. Rusin, W. Szeja, and G. Grynkiewicz, “Absorption and metabolism of biologically active genistein derivatives in colon carcinoma cell line (CACO-2),” Acta Poloniae Pharmaceutica—Drug Research, vol. 71, no. 6, pp. 1037–1044, 2014. View at Google Scholar · View at Scopus
  69. Z. Guo, X. Hu, Z. Xing et al., “Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway,” Molecular and Cellular Biochemistry, vol. 406, no. 1-2, pp. 111–119, 2015. View at Publisher · View at Google Scholar
  70. Y. Wang, A. Han, E. Chen et al., “The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells,” International Journal of Oncology, vol. 46, no. 5, pp. 1924–1934, 2015. View at Publisher · View at Google Scholar
  71. R.-H. Chou, S.-C. Hsieh, Y.-L. Yu, M.-H. Huang, Y.-C. Huang, and Y.-H. Hsieh, “Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway,” PLoS ONE, vol. 8, no. 8, Article ID e71983, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. K. Sak and H. Everaus, “Chemomodulating effects of flavonoids in human leukemia cells,” Anti-Cancer Agents in Medicinal Chemistry, vol. 15, no. 9, pp. 1112–1126, 2015. View at Google Scholar
  73. J. Schümann, J. Prockl, A. K. Kiemer, A. M. Vollmar, R. Bang, and G. Tiegs, “Silibinin protects mice from T cell-dependent liver injury,” Journal of Hepatology, vol. 39, no. 3, pp. 333–340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Vargas-Mendoza, E. Madrigal-Santillán, A. Morales-González et al., “Hepatoprotective effect of silymarin,” World Journal of Hepatology, vol. 6, no. 3, pp. 144–149, 2014. View at Publisher · View at Google Scholar
  75. T. Nishikawa, T. Nakajima, M. Moriguchi et al., “A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins,” Journal of Hepatology, vol. 44, no. 6, pp. 1074–1082, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. R.-R. Liang, S. Zhang, J.-A. N. Qi et al., “Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling,” International Journal of Oncology, vol. 41, no. 3, pp. 969–978, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. T.-C. Yeh, P.-C. Chiang, T.-K. Li et al., “Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult,” Biochemical Pharmacology, vol. 73, no. 6, pp. 782–792, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. Y. Gu, C.-F. Zhu, Y.-L. Dai, Q. Zhong, and B. Sun, “Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 15, no. 39, pp. 4952–4957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. L. Zhao, Z. Chen, J. Wang et al., “Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 3, pp. 481–489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Zhu, L. Zhao, L. Zhu et al., “Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinβ1 and its related pathway,” Toxicology and Applied Pharmacology, vol. 259, no. 3, pp. 387–394, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Wen, J. Wu, H. Luo, and H. Zhang, “Galangin induces autophagy through upregulation of p53 in HepG2 cells,” Pharmacology, vol. 89, no. 5-6, pp. 247–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. A. B. Granado-Serrano, M. A. Martín, L. Bravo, L. Goya, and S. Ramos, “Time-course regulation of quercetin on cell survival/proliferation pathways in human hepatoma cells,” Molecular Nutrition and Food Research, vol. 52, no. 4, pp. 457–464, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Wang, J. Zhang, L. Liu, S. Sharma, and Q. Dong, “Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl,” PLoS ONE, vol. 7, no. 12, Article ID e51764, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Moher, D. J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D. F. Stroup, “Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses,” The Lancet, vol. 354, no. 9193, pp. 1896–1900, 1999. View at Publisher · View at Google Scholar · View at Scopus
  85. R. N. Abou El Naga, S. S. Azab, E. El-Demerdash, S. Shaarawy, M. El-Merzabani, and E.-S. M. Ammar, “Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals,” Life Sciences, vol. 92, no. 10, pp. 555–561, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Wang, X. Ren, C. Deng et al., “Mechanism of the inhibition of the STAT3 signaling pathway by EGCG,” Oncology Reports, vol. 30, no. 6, pp. 2691–2696, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Jin, Y. Chang, W. Wei et al., “Prostanoid EP1 receptor as the target of (−)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro,” Acta Pharmacologica Sinica, vol. 33, no. 5, pp. 701–709, 2012. View at Publisher · View at Google Scholar
  88. C.-H. Huang, S.-J. Tsai, Y.-J. Wang, M.-H. Pan, J.-Y. Kao, and T.-D. Way, “EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells,” Molecular Nutrition and Food Research, vol. 53, no. 9, pp. 1156–1165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. Shirakami, M. Shimizu, S. Adachi et al., “(–)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor–vascular endothelial growth factor receptor axis,” Cancer Science, vol. 100, no. 10, pp. 1957–1962, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. H.-H. Tang, M. Zhou, and G. Liang, “Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU,” Ai Zheng, vol. 27, no. 10, pp. 1056–1064, 2008. View at Google Scholar · View at Scopus
  91. J. L. Sang, W. L. Ki, J. H. Haeng, Y. C. Ji, Y. K. Seo, and J. L. Hyong, “Phenolic phytochemicals derived from red pine (Pinus densiflora) inhibit the invasion and migration of SK-Hep-1 human hepatocellular carcinoma cells,” Annals of the New York Academy of Sciences, vol. 1095, pp. 536–544, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. Q. Zhang, X. Tang, Q. Lu, Z. Zhang, J. Rao, and A. D. Le, “Green tea extract and (−)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1α protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells,” Molecular Cancer Therapeutics, vol. 5, no. 5, pp. 1227–1238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. Z. Wang, C. Jiang, W. Chen et al., “Baicalein induces apoptosis and autophagy via endoplasmic reticulum stress in hepatocellular carcinoma cells,” BioMed Research International, vol. 2014, Article ID 732516, 13 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. Y.-W. Chiu, T.-H. Lin, W.-S. Huang et al., “Baicalein inhibits the migration and invasive properties of human hepatoma cells,” Toxicology and Applied Pharmacology, vol. 255, no. 3, pp. 316–326, 2011. View at Publisher · View at Google Scholar
  95. H.-M. Kuo, H.-C. Tsai, Y.-L. Lin et al., “Mitochondrial-dependent caspase activation pathway is involved in baicalein-induced apoptosis in human hepatoma J5 cells,” International Journal of Oncology, vol. 35, no. 4, pp. 717–724, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. W.-H. Chang, C.-H. Chen, and F.-J. Lu, “Different effects of baicalein, baicalin and wogonin on mitochondrial function, glutathione content and cell cycle progression in human hepatoma cell lines,” Planta Medica, vol. 68, no. 2, pp. 128–132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. Hu, Y. Yang, Q.-D. You et al., “Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity,” Biochemical and Biophysical Research Communications, vol. 351, no. 2, pp. 521–527, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. S.-D. Wang, B.-C. Chen, S.-T. Kao, C.-J. Liu, and C.-C. Yeh, “Genistein inhibits tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells,” BMC Complementary and Alternative Medicine, vol. 14, article 26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. Y. Ma, J. Wang, L. Liu et al., “Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB,” Cancer Letters, vol. 301, no. 1, pp. 75–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. S.-C. Fang, C.-L. Hsu, H.-T. Lin, and G.-C. Yen, “Anticancer effects of flavonoid derivatives isolated from Millettia reticulata benth in sk-hep-1 human hepatocellular carcinoma cells,” Journal of Agricultural and Food Chemistry, vol. 58, no. 2, pp. 814–820, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. H. Jiang, Y. Ma, X. Chen et al., “Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma,” Cancer Science, vol. 101, no. 4, pp. 975–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. C.-H. Chen, T.-S. Huang, C.-H. Wong et al., “Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 cells,” Food and Chemical Toxicology, vol. 47, no. 3, pp. 638–644, 2009. View at Publisher · View at Google Scholar
  103. L. Su, X. Chen, J. Wu et al., “Galangin inhibits proliferation of hepatocellular carcinoma cells by inducing endoplasmic reticulum stress,” Food and Chemical Toxicology, vol. 62, pp. 810–816, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. H.-T. Zhang, H. Luo, J. Wu et al., “Galangin induces apoptosis of hepatocellular carcinoma cells via the mitochondrial pathway,” World Journal of Gastroenterology, vol. 16, no. 27, pp. 3377–3384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. J.-L. Zhao, J. Zhao, and H.-J. Jiao, “Synergistic growth-suppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells,” Applied Biochemistry and Biotechnology, vol. 172, no. 2, pp. 784–791, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. V. R. Vásquez-Garzón, J. R. MacIas-Pérez, M. N. Jiménez-García, V. Villegas, S. Fattel-Fazenta, and S. Villa-Treviño, “The chemopreventive capacity of quercetin to induce programmed cell death in hepatocarcinogenesis,” Toxicologic Pathology, vol. 41, no. 6, pp. 857–865, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Zhou, L. Fang, W.-X. Yao et al., “Effect of quercetin on heat shock protein expression in human hepatocellular carcinoma HepG2 cells determined by SILAC,” Chinese Journal of Oncology, vol. 33, no. 10, pp. 737–741, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. A. B. Granado-Serrano, M. A. Martín, L. Bravo, L. Goya, and S. Ramos, “Quercetin modulates NF-kappa B and AP-1/JNK pathways to induce cell death in human hepatoma cells,” Nutrition and Cancer, vol. 62, no. 3, pp. 390–401, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. Y.-F. Chang, Y.-C. Hsu, H.-F. Hung et al., “Quercetin induces oxidative stress and potentiates the apoptotic action of 2-methoxyestradiol in human hepatoma cells,” Nutrition and Cancer, vol. 61, no. 5, pp. 735–745, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. J. Y. Kim, E. H. Kim, S. S. Park, J. H. Lim, T. K. Kwon, and K. S. Choi, “Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation,” Journal of Cellular Biochemistry, vol. 105, no. 6, pp. 1386–1398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. W. Cui, F. Gu, and K.-Q. Hu, “Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice,” World Journal of Gastroenterology, vol. 15, no. 16, pp. 1943–1950, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. P. García-Maceira and J. Mateo, “Silibinin inhibits hypoxia-inducible factor-1α and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy,” Oncogene, vol. 28, no. 3, pp. 313–324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. J. J. Lah, W. Cui, and K.-Q. Hu, “Effects and mechanisms of silibinin on human hepatoma cell lines,” World Journal of Gastroenterology, vol. 13, no. 40, pp. 5299–5305, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. L. Varghese, C. Agarwal, A. Tyagi, R. P. Singh, and R. Agarwal, “Silibinin efficacy against human hepatocellular carcinoma,” Clinical Cancer Research, vol. 11, no. 23, pp. 8441–8448, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. V. Crespy and G. Williamson, “A review of the health effects of green tea catechins in in vivo animal models,” Journal of Nutrition, vol. 134, no. 12, supplement, pp. 3431S–3440S, 2004. View at Google Scholar · View at Scopus
  116. G. Z. Yang, Z. J. Wang, F. Bai et al., “Epigallocatechin-3-gallate protects HUVECs from PM2.5-induced oxidative stress injury by activating critical antioxidant pathways,” Molecules, vol. 20, no. 4, pp. 6626–6639, 2015. View at Publisher · View at Google Scholar
  117. M. Nihal, N. Ahmad, H. Mukhtar, and G. S. Wood, “Anti-proliferative and proapoptotic effects of (−)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma,” International Journal of Cancer, vol. 114, no. 4, pp. 513–521, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. H. S. Lee, J.-H. Jun, E.-H. Jung, B. A. Koo, and Y. S. Kim, “Epigalloccatechin-3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation,” Molecules, vol. 19, no. 8, pp. 12150–12172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. M. S. Baliga, S. Meleth, and S. K. Katiyar, “Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems,” Clinical Cancer Research, vol. 11, no. 5, pp. 1918–1927, 2005. View at Publisher · View at Google Scholar · View at Scopus
  120. J.-I. Sonoda, R. Ikeda, Y. Baba et al., “Green tea catechin, epigallocatechin-3-gallate, attenuates the cell viability of human non-small-cell lung cancer A549 cells via reducing Bcl-xL expression,” Experimental and Therapeutic Medicine, vol. 8, no. 1, pp. 59–63, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. D. Zhang, M. Al-Hendy, G. Richard-Davis, V. Montgomery-Rice, V. Rajaratnam, and A. Al-Hendy, “Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells,” Fertility and Sterility, vol. 94, no. 5, pp. 1887–1893, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. C. Mayr, A. Wagner, D. Neureiter et al., “The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells,” BMC Complementary and Alternative Medicine, vol. 15, article 194, 2015. View at Publisher · View at Google Scholar
  123. B. N. Singh, S. Shankar, and R. K. Srivastava, “Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications,” Biochemical Pharmacology, vol. 82, no. 12, pp. 1807–1821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. H. Mukhtar and N. Ahmad, “Tea polyphenols: prevention of cancer and optimizing health,” The American Journal of Clinical Nutrition, vol. 71, no. 6, supplement, pp. 1698S–1704S, 2000. View at Google Scholar
  125. M. Shimizu and I. B. Weinstein, “Modulation of signal transduction by tea catechins and related phytochemicals,” Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis, vol. 591, no. 1-2, pp. 147–160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. M. Shimizu, A. Deguchi, J. T. E. Lim, H. Moriwaki, L. Kopelovich, and I. B. Weinstein, “(−)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells,” Clinical Cancer Research, vol. 11, no. 7, pp. 2735–2746, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Masuda, M. Suzui, J. T. E. Lim, and I. B. Weinstein, “Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells,” Clinical Cancer Research, vol. 9, no. 9, pp. 3486–3491, 2003. View at Google Scholar · View at Scopus
  128. V. M. Adhami, I. A. Siddiqui, N. Ahmad, S. Gupta, and H. Mukhtar, “Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer,” Cancer Research, vol. 64, no. 23, pp. 8715–8722, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. D. Jung, M. S. Kim, B. A. Shin et al., “EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells,” British Journal of Cancer, vol. 84, no. 6, pp. 844–850, 2001. View at Publisher · View at Google Scholar · View at Scopus
  130. G. Basini, F. Bianco, and F. Grasselli, “EGCG, a major component of green tea, inhibits VEGF production by swine granulosa cells,” BioFactors, vol. 23, no. 1, pp. 25–33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. S. Shankar, S. Ganapathy, S. R. Hingorani, and R. K. Srivastava, “EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer,” Frontiers in Bioscience, vol. 13, no. 2, pp. 440–452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. T. Sen, S. Moulik, A. Dutta et al., “Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7,” Life Sciences, vol. 84, no. 7-8, pp. 194–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. S. K. Denduluri, O. Idowu, Z. Wang et al., “Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance,” Genes & Diseases, vol. 2, no. 1, pp. 13–25, 2015. View at Publisher · View at Google Scholar
  134. B. B. Aggarwal, G. Sethi, S. A. Kwang et al., “Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution,” Annals of the New York Academy of Sciences, vol. 1091, pp. 151–169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  135. D. G. Hardie, “Molecular pathways: is AMPK a friend or a foe in cancer?” Clinical Cancer Research, vol. 21, no. 17, pp. 3836–3840, 2015. View at Publisher · View at Google Scholar
  136. R. Kaufmann, S. Rahn, K. Pollrich et al., “Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4,” Journal of Cellular Physiology, vol. 211, no. 3, pp. 699–707, 2007. View at Google Scholar
  137. S.-Y. Sun, N. Hail Jr., and R. Lotan, “Apoptosis as a novel target for cancer chemoprevention,” Journal of the National Cancer Institute, vol. 96, no. 9, pp. 662–672, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. X.-P. Chen, S.-Q. He, H.-P. Wang, Y.-Z. Zhao, and W.-G. Zhang, “Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 9, no. 11, pp. 2433–2440, 2003. View at Google Scholar · View at Scopus
  139. D. G. Breckenridge, M. Germain, J. P. Mathai, M. Nguyen, and G. C. Shore, “Regulation of apoptosis by endoplasmic reticulum pathways,” Oncogene, vol. 22, no. 53, pp. 8608–8618, 2003. View at Publisher · View at Google Scholar · View at Scopus
  140. K. Révész, A. Tütto, and L. Konta, “Effect of green tea flavanols on the functions of the endoplasmic reticulum,” Orvosi Hetilap, vol. 148, no. 40, pp. 1903–1907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  141. F. Dituri, A. Mazzocca, J. Fernando et al., “Differential inhibition of the TGF-β signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-β receptor type II,” PLoS ONE, vol. 8, no. 6, Article ID e67109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  142. W. Liu, H. Nakamura, T. Tsujimura et al., “Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor,” Cancer Science, vol. 97, no. 8, pp. 768–773, 2006. View at Publisher · View at Google Scholar · View at Scopus
  143. M. A. Kern, A. M. Haugg, A. F. Koch et al., “Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma,” Cancer Research, vol. 66, no. 14, pp. 7059–7066, 2006. View at Publisher · View at Google Scholar · View at Scopus
  144. D. G. Menter and R. N. DuBois, “Prostaglandins in cancer cell adhesion, migration, and invasion,” International Journal of Cell Biology, vol. 2012, Article ID 723419, 21 pages, 2012. View at Publisher · View at Google Scholar
  145. C. Han, G. K. Michalopoulos, and T. Wu, “Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells,” Journal of Cellular Physiology, vol. 207, no. 1, pp. 261–270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  146. M. W. Roomi, J. C. Monterrey, T. Kalinovsky, M. Rath, and A. Niedzwiecki, “Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines,” Oncology Reports, vol. 24, no. 3, pp. 747–757, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. K. H. Kim, Y. D. Park, H. Park et al., “Synthesis and biological evaluation of a novel baicalein glycoside as an anti-inflammatory agent,” European Journal of Pharmacology, vol. 744, pp. 147–156, 2014. View at Publisher · View at Google Scholar
  148. J. Y. Wu, K. T. Chung, Y. W. Liu, F. J. Lu, R. S. Tsai, and C. H. Chen, “Synthesis and biological evaluation of novel C(6) modified baicalein derivatives as antioxidative agents,” Journal of Agricultural and Food Chemistry, vol. 56, no. 8, pp. 2838–2845, 2008. View at Publisher · View at Google Scholar
  149. L. Gao, C. Li, R.-Y. Yang et al., “Ameliorative effects of baicalein in MPTP-induced mouse model of Parkinson's disease: a microarray study,” Pharmacology Biochemistry and Behavior, vol. 133, pp. 155–163, 2015. View at Publisher · View at Google Scholar
  150. Y. Huang, S.-Y. Tsang, X. Yao, and Z.-Y. Chen, “Biological properties of baicalein in cardiovascular system,” Current Drug Target—Cardiovascular & Hematological Disorders, vol. 5, no. 2, pp. 177–184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Ahad, M. Mujeeb, H. Ahsan, and W. A. Siddiqui, “Prophylactic effect of baicalein against renal dysfunction in type 2 diabetic rats,” Biochimie, vol. 106, pp. 101–110, 2014. View at Publisher · View at Google Scholar · View at Scopus
  152. Y. Zhang, L. Shan, Y. Hua et al., “Baicalein selectively induces apoptosis in activated lymphocytes and ameliorates concanavalin a-induced hepatitis in mice,” PLoS ONE, vol. 8, no. 7, Article ID e69592, 2013. View at Publisher · View at Google Scholar
  153. H.-J. Chen, T.-M. Liang, I.-J. Lee, Y.-T. Huang, and Y.-L. Lin, “Scutellariae radix suppresses LPS-induced liver endothelial cell activation and inhibits hepatic stellate cell migration,” Journal of Ethnopharmacology, vol. 150, no. 3, pp. 835–842, 2013. View at Publisher · View at Google Scholar
  154. H.-B. Zhang, P. Lu, Q.-Y. Guo, Z.-H. Zhang, and X.-Y. Meng, “Baicalein induces apoptosis in esophageal squamous cell carcinoma cells through modulation of the PI3K/Akt pathway,” Oncology Letters, vol. 5, no. 2, pp. 722–728, 2013. View at Publisher · View at Google Scholar · View at Scopus
  155. J. Y. Wu, K. W. Tsai, Y. Z. Li et al., “Anti-bladder-tumor effect of Baicalein from Scutellaria baicalensis Georgi and its application in vivo,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 579751, 12 pages, 2013. View at Publisher · View at Google Scholar
  156. D. H. Kim, M. A. Hossain, Y. J. Kang et al., “Baicalein, an active component of Scutellaria baicalensis Georgi, induces apoptosis in human colon cancer cells and prevents AOM/DSS-induced colon cancer in mice,” International Journal of Oncology, vol. 43, no. 5, pp. 1652–1658, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. G. Donald, K. Hertzer, and G. Eibl, “Baicalein—an intriguing therapeutic phytochemical in pancreatic cancer,” Current Drug Targets, vol. 13, no. 14, pp. 1772–1776, 2012. View at Publisher · View at Google Scholar · View at Scopus
  158. P. Puri and A. Chandra, “Autophagy modulation as a potential therapeutic target for liver diseases,” Journal of Clinical and Experimental Hepatology, vol. 4, no. 1, pp. 51–59, 2014. View at Publisher · View at Google Scholar
  159. Y. Y. Zhou, Y. Li, W. Q. Jiang, and L. F. Zhou, “MAPK/JNK signalling: a potential autophagy regulation pathway,” Bioscience Reports, vol. 35, no. 3, Article ID e00199, 2015. View at Publisher · View at Google Scholar
  160. F. Wang, J. L. Yang, K. K. Yu et al., “Activation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma,” Molecular Cancer, vol. 14, article 10, 2015. View at Publisher · View at Google Scholar
  161. T. Luedde and R. F. Schwabe, “NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma,” Nature Reviews Gastroenterology & Hepatology, vol. 8, no. 2, pp. 108–118, 2011. View at Publisher · View at Google Scholar
  162. D.-P. Ou, Y.-M. Tao, F.-Q. Tang, and L.-Y. Yang, “The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases,” International Journal of Cancer, vol. 120, no. 6, pp. 1208–1214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  163. T. Itoh, Y. Hayashi, T. Kanamaru et al., “Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 15, no. 4, pp. 422–430, 2000. View at Publisher · View at Google Scholar · View at Scopus
  164. J. Cheng, J. Qi, X.-T. Li et al., “ATRA and genistein synergistically inhibit the metastatic potential of human lung adenocarcinoma cells,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 3, pp. 47220–4227, 2015. View at Google Scholar
  165. DG. Pons, M. Nadal-Serrano, M. Torrens-Mas, J. Oliver, and P. Roca, “The phytoestrogen genistein affects breast cancer cells treatment depending on the ERα/ERβ ratio,” Journal of Cellular Biochemistry, 2015. View at Publisher · View at Google Scholar
  166. W. Huang, C. Wan, Q. Luo, Z. Huang, and Q. Luo, “Genistein-inhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancer,” International Journal of Molecular Sciences, vol. 15, no. 3, pp. 3432–3443, 2014. View at Publisher · View at Google Scholar
  167. Y. Luo, S. X. Wang, Z. Q. Zhou et al., “Apoptotic effect of genistein on human colon cancer cells via inhibiting the nuclear factor-kappa B (NF-κB) pathway,” Tumor Biology, vol. 35, no. 11, pp. 11483–11488, 2014. View at Publisher · View at Google Scholar
  168. M. N. Dastjerdi, F. Kavoosi, A. Valiani et al., “Inhibitory effect of genistein on PLC/PRF5 hepatocellular carcinoma cell line,” International Journal of Preventive Medicine, vol. 6, article 54, 2015. View at Publisher · View at Google Scholar
  169. Y. Wu, L. Zhang, R. Na et al., “Plasma genistein and risk of prostate cancer in Chinese population,” International Urology and Nephrology, vol. 47, no. 6, pp. 965–970, 2015. View at Publisher · View at Google Scholar
  170. Y.-S. Li, L.-P. Wu, K.-H. Li et al., “Involvement of nuclear factor κB (NF-κB) in the downregulation of cyclo-oxygenase-2 (COX-2) by genistein in gastric cancer cells,” Journal of International Medical Research, vol. 39, no. 6, pp. 2141–2150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  171. M. S. Tsuboy, J. C. Marcarini, A. O. de Souza et al., “Genistein at maximal physiologic serum levels induces G0/G1 arrest in MCF-7 and HB4a cells, but not apoptosis,” Journal of Medicinal Food, vol. 17, no. 2, pp. 218–225, 2014. View at Publisher · View at Google Scholar · View at Scopus
  172. S. H. Kim, C. W. Kim, S. Y. Jeon, R. E. Go, K. A. Hwang, and K. C. Choi, “Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models,” Laboratory Animal Research, vol. 30, no. 4, pp. 143–150, 2014. View at Publisher · View at Google Scholar
  173. Y. Sun, W. Z. Liu, T. Liu, X. Feng, N. Yang, and H. F. Zhou, “Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis,” Journal of Receptors and Signal Transduction, 2015. View at Publisher · View at Google Scholar
  174. F. van Zijl, G. Zulehner, M. Petz et al., “Epithelial-mesenchymal transition in hepatocellular carcinoma,” Future Oncology, vol. 5, no. 8, pp. 1169–1179, 2009. View at Publisher · View at Google Scholar · View at Scopus
  175. M. Ye, Q. Wang, W. Zhang, Z. Li, Y. Wang, and R. Hu, “Oroxylin A exerts anti-inflammatory activity on lipopolysaccharide-induced mouse macrophage via Nrf2/ARE activation,” Biochemistry and Cell Biology, vol. 92, no. 5, pp. 337–348, 2014. View at Publisher · View at Google Scholar · View at Scopus
  176. S.-C. Ma, J. Du, P. P.-H. But et al., “Antiviral Chinese medicinal herbs against respiratory syncytial virus,” Journal of Ethnopharmacology, vol. 79, no. 2, pp. 205–211, 2002. View at Publisher · View at Google Scholar · View at Scopus
  177. H.-T. Trinh, E.-H. Joh, H.-Y. Kwak, N.-I. Baek, and D.-H. Kim, “Anti-pruritic effect of baicalin and its metabolites, baicalein and oroxylin A, in mice,” Acta Pharmacologica Sinica, vol. 31, no. 6, pp. 718–724, 2010. View at Publisher · View at Google Scholar · View at Scopus
  178. D. H. Kim, S. J. Jeon, K. H. Son et al., “Effect of the flavonoid, oroxylin A, on transient cerebral hypoperfusion-induced memory impairment in mice,” Pharmacology Biochemistry and Behavior, vol. 85, no. 3, pp. 658–668, 2006. View at Publisher · View at Google Scholar · View at Scopus
  179. R. Zhu, G. Zeng, Y. Chen et al., “Oroxylin A accelerates liver regeneration in CCI4-induced acute liver injury mice,” PLoS ONE, vol. 8, no. 8, Article ID e71612, 2013. View at Publisher · View at Google Scholar · View at Scopus
  180. L. Wei, Q. Dai, Y. Zhou et al., “Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II,” Biochimica et Biophysica Acta: General Subjects, vol. 1830, no. 6, pp. 3835–3845, 2013. View at Publisher · View at Google Scholar · View at Scopus
  181. L. Wei, Y. Zhou, C. Qiao et al., “Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization,” Cell Death and Disease, vol. 6, no. 4, Article ID e1714, 2015. View at Publisher · View at Google Scholar
  182. Y. Yang, Y. Hu, H.-Y. Gu et al., “Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells,” Journal of Pharmacy and Pharmacology, vol. 60, no. 11, pp. 1459–1463, 2008. View at Publisher · View at Google Scholar · View at Scopus
  183. C. Qiao, L. Wei, Q. Dai et al., “UCP2-related mitochondrial pathway participates in oroxylin A-induced apoptosis in human colon cancer cells,” Journal of Cellular Physiology, vol. 230, no. 5, pp. 1054–1063, 2015. View at Publisher · View at Google Scholar · View at Scopus
  184. H.-N. Li, F.-F. Nie, W. Liu et al., “Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo,” Toxicology, vol. 257, no. 1-2, pp. 80–85, 2009. View at Publisher · View at Google Scholar
  185. H. Hui, Y. Chen, H. Yang et al., “Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα,” International Journal of Cancer, vol. 134, no. 5, pp. 1195–1206, 2014. View at Publisher · View at Google Scholar · View at Scopus
  186. X. Meng, D. A. Franklin, J. Dong, and Y. Zhang, “MDM2-p53 pathway in hepatocellular carcinoma,” Cancer Research, vol. 74, no. 24, pp. 7161–7167, 2014. View at Publisher · View at Google Scholar
  187. R. Mu, Q. Qi, H. Gu et al., “Involvement of p53 in oroxylin A-induced apoptosis in cancer cells,” Molecular Carcinogenesis, vol. 48, no. 12, pp. 1159–1169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  188. T. P. T. Cushnie and A. J. Lamb, “Assessment of the antibacterial activity of galangin against 4-quinolone resistant strains of Staphylococcus aureus,” Phytomedicine, vol. 13, no. 3, pp. 187–191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  189. G. Duthie and P. Morrice, “Antioxidant capacity of flavonoids in hepatic microsomes is not reflected by antioxidant effects in vivo,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 165127, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  190. H. H. Kim, Y. Bae, and S. H. Kim, “Galangin attenuates mast cell-mediated allergic inflammation,” Food and Chemical Toxicology, vol. 57, pp. 209–216, 2013. View at Publisher · View at Google Scholar
  191. S. Kumar and K. R. Alagawadi, “Anti-obesity effects of galangin, a pancreatic lipase inhibitor in cafeteria diet fed female rats,” Pharmaceutical Biology, vol. 51, no. 5, pp. 607–613, 2013. View at Publisher · View at Google Scholar · View at Scopus
  192. S. Li, C. Wu, L. Zhu et al., “By improving regional cortical blood flow, attenuating mitochondrial dysfunction and sequential apoptosis galangin acts as a potential neuroprotective agent after acute ischemic stroke,” Molecules, vol. 17, no. 11, pp. 13403–13423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  193. S. Kapoor, “Galangin and its emerging anti-neoplastic effects,” Cytotechnology, vol. 65, no. 4, pp. 467–468, 2013. View at Publisher · View at Google Scholar
  194. X. Zhao and J. Zhang, “Inhibitory effect of galangin on DNA topoisomerases in lung cancer cells,” Zhong Nan Da Xue Xue Bao Yi Xue Ban, vol. 40, no. 5, pp. 479–485, 2015. View at Publisher · View at Google Scholar
  195. L. Zhu, Q. Luo, J. Bi, J. Ding, S. Ge, and F. Chen, “Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo,” Chemico-Biological Interactions, vol. 224, pp. 149–156, 2014. View at Publisher · View at Google Scholar
  196. T. J. Murray, X. Yang, and D. H. Sherr, “Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A,” Breast Cancer Research, vol. 8, no. 2, article R17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  197. T. K. Ha, M. E. Kim, J. H. Yoon, S. J. Bae, J. Yeom, and J. S. Lee, “Galangin induces human colon cancer cell death via the mitochondrial dysfunction and caspase-dependent pathway,” Experimental Biology and Medicine, vol. 238, no. 9, pp. 1047–1054, 2013. View at Publisher · View at Google Scholar · View at Scopus
  198. H. Huang, A. Y. Chen, Y. Rojanasakul, X. Ye, G. O. Rankin, and Y. C. Chen, “Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis,” Journal of Functional Foods, vol. 15, pp. 464–475, 2015. View at Publisher · View at Google Scholar
  199. A. Monasterio, M. C. Urdaci, I. V. Pinchuk, N. López-Moratalla, and J. J. Martínez-Irujo, “Flavonoids induce apoptosis in human leukemia U937 cells through caspase- and caspase-calpain-dependent pathways,” Nutrition and Cancer, vol. 50, no. 1, pp. 90–100, 2004. View at Publisher · View at Google Scholar · View at Scopus
  200. W. Zhang, Y. Lan, Q. Huang, and Z. Hua, “Galangin induces B16F10 melanoma cell apoptosis via mitochondrial pathway and sustained activation of p38 MAPK,” Cytotechnology, vol. 65, no. 3, pp. 447–455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  201. C. C. Pan, S. Kumar, N. Shah et al., “Endoglin regulation of Smad2 function mediates beclin1 expression and endothelial autophagy,” The Journal of Biological Chemistry, vol. 290, no. 24, pp. 14884–14892, 2015. View at Publisher · View at Google Scholar
  202. S. T. Chien, M. D. Shi, Y. C. Lee, C. C. Te, and Y. W. Shih, “Galangin, a novel dietary flavonoid, attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells,” Cancer Cell International, vol. 15, article 15, 2015. View at Publisher · View at Google Scholar
  203. V. S. Rogovskiĭ, N. L. Shimanovskiĭ, and A. I. Matiushin, “Antihypertensive and neuroprotective activity of quercetin and its derivatives,” Eksp Klin Farmakol, vol. 75, no. 9, pp. 37–41, 2012. View at Google Scholar
  204. R. Huang, T. Zhong, and H. Wu, “Quercetin protects against lipopolysaccharide-induced acute lung injury in rats through suppression of inflammation and oxidative stress,” Archives of Medical Science, vol. 11, no. 2, pp. 427–432, 2015. View at Publisher · View at Google Scholar
  205. M. Belviranli and N. Okudan, “Well-known antioxidants and newcomers in sport nutrition: coenzyme Q10, quercetin, resveratrol, pterostilbene, pycnogenol and astaxanthin,” in Antioxidants in Sport Nutrition, M. Lamprecht, Ed., chapter 5, CRC Press, Boca Raton, Fla, USA, 2015. View at Google Scholar
  206. A. M. L. Hossion and K. Sasaki, “Novel quercetin glycosides as potent anti-MRSA and anti-VRE agents,” Recent Patents on Anti-Infective Drug Discovery, vol. 8, no. 3, pp. 198–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  207. H. M. Eid, A. Nachar, F. Thong, G. Sweeney, and P. S. Haddad, “The molecular basis of the antidiabetic action of quercetin in cultured skeletal muscle cells and hepatocytes,” Pharmacognosy Magazine, vol. 11, no. 41, pp. 74–81, 2015. View at Publisher · View at Google Scholar
  208. M. Waseem and S. Parvez, “Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin,” Protoplasma, 2015. View at Publisher · View at Google Scholar
  209. E. Rajesh, L. S. Sankari, L. Malathi, and J. R. Krupaa, “Naturally occurring products in cancer therapy,” Journal of Pharmacy And Bioallied Sciences, vol. 7, supplement 1, pp. S181–S183, 2015. View at Publisher · View at Google Scholar
  210. X. Zhao and J. Zhang, “Mechanisms for quercetin in prevention of lung cancer cell growth and metastasis,” Zhong Nan Da Xue Xue Bao Yi Xue Ban, vol. 40, no. 6, pp. 592–597, 2015. View at Publisher · View at Google Scholar
  211. J.-Y. Zhang, M.-T. Lin, M.-J. Zhou et al., “Combinational treatment of curcumin and quercetin against gastric cancer MGC-803 cells in vitro,” Molecules, vol. 20, no. 6, pp. 11524–11534, 2015. View at Publisher · View at Google Scholar
  212. M. G. Refolo, R. D'Alessandro, N. Malerba et al., “Anti proliferative and pro apoptotic effects of flavonoid quercetin are mediated by CB1 receptor in human colon cancer cell lines,” Journal of Cellular Physiology, vol. 230, no. 12, pp. 2973–2980, 2015. View at Publisher · View at Google Scholar
  213. F. Yang, L. Song, H. Wang, J. Wang, Z. Xu, and N. Xing, “Combination of quercetin and 2-methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells Xenograft tumor growth,” PLoS ONE, vol. 10, no. 5, Article ID e0128277, 2015. View at Publisher · View at Google Scholar
  214. J. Zhou, J. Gong, C. Ding, and G. Chen, “Quercetin induces the apoptosis of human ovarian carcinoma cells by upregulating the expression of microRNA-145,” Molecular Medicine Reports, vol. 12, no. 2, pp. 3127–3131, 2015. View at Publisher · View at Google Scholar
  215. Y. Hu, S. Wang, X. Wu et al., “Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma,” Journal of Ethnopharmacology, vol. 149, no. 3, pp. 601–612, 2013. View at Publisher · View at Google Scholar
  216. V. Vásquez-Garzón, J. Arellanes-Robledo, R. García-Román, D. Aparicio-Rautista, and S. Villa-Treviño, “Inhibition of reactive oxygen species and pre-neoplastic lesions by quercetin through an antioxidant defense mechanism,” Free Radical Research, vol. 43, no. 2, pp. 128–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  217. Y.-F. Chang, N.-W. Chi, and J.-J. Wang, “Reactive oxygen species production is involved in quercetin-induced apoptosis in human hepatoma cells,” Nutrition and Cancer, vol. 55, no. 2, pp. 201–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  218. S. Öztürk, K. Schleich, and I. N. Lavrik, “Cellular FLICE-like inhibitory proteins (c-FLIPs): fine-tuners of life and death decisions,” Experimental Cell Research, vol. 318, no. 11, pp. 1324–1331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  219. W. J. Lu, N. P. Lee, S. Fatima, and J. M. Luk, “Heat shock proteins in cancer: signaling pathways, tumor markers and molecular targets in liver malignancy,” Protein and Peptide Letters, vol. 16, no. 5, pp. 508–516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  220. A. Sharma, A. K. Upadhyay, and M. K. Bhat, “Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells,” Cancer Biology and Therapy, vol. 8, no. 22, pp. 2106–2113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  221. K. Wellington and B. Jarvis, “Silymarin: a review of its clinical properties in the management of hepatic disorders,” BioDrugs, vol. 15, no. 7, pp. 465–489, 2001. View at Publisher · View at Google Scholar · View at Scopus
  222. R. K. Dhiman and Y. K. Chawla, “Herbal medicines for liver diseases,” Digestive Diseases and Sciences, vol. 50, no. 10, pp. 1807–1812, 2005. View at Publisher · View at Google Scholar · View at Scopus
  223. G. Mallikarjuna, S. Dhanalakshmi, R. P. Singh, C. Agarwal, and R. Agarwal, “Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling,” Cancer Research, vol. 64, no. 17, pp. 6349–6356, 2004. View at Publisher · View at Google Scholar · View at Scopus
  224. X. Wang, E. Gocek, V. Novik, J. S. Harrison, M. Danilenko, and G. P. Studzinski, “Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and upregulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D3,” Cell Cycle, vol. 9, no. 22, pp. 4542–4551, 2010. View at Publisher · View at Google Scholar · View at Scopus
  225. D. K. Nambiar, P. Rajamani, and R. P. Singh, “Silibinin attenuates ionizing radiation-induced pro-angiogenic response and EMT in prostate cancer cells,” Biochemical and Biophysical Research Communications, vol. 456, no. 1, pp. 262–268, 2015. View at Publisher · View at Google Scholar · View at Scopus
  226. R. Kumar, G. Deep, and R. Agarwal, “An overview of ultraviolet B radiation-induced skin cancer chemoprevention by silibinin,” Current Pharmacology Reports, vol. 1, no. 3, pp. 206–215, 2015. View at Publisher · View at Google Scholar
  227. Z. Liang, Y. Yang, H. Wang et al., “Inhibition of SIRT1 signaling sensitizes the antitumor activity of silybin against human lung adenocarcinoma cells in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 13, no. 7, pp. 1860–1872, 2014. View at Publisher · View at Google Scholar · View at Scopus
  228. M. B. Pirouzpanah, M. Sabzichi, S. Pirouzpanah, H. Chavoshi, and N. Samadi, “Silibilin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 5, pp. 2087–2092, 2015. View at Publisher · View at Google Scholar
  229. S. Kumar, K. Raina, C. Agarwal, and R. Agarwal, “Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals,” Oncotarget, vol. 5, no. 13, pp. 4972–4989, 2014. View at Publisher · View at Google Scholar · View at Scopus
  230. K. Wu, Z. Ning, J. Zeng et al., “Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness,” Cellular Signalling, vol. 25, no. 12, pp. 2625–2633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  231. M. Osaki, M. Oshimura, and H. Ito, “PI3K-Akt pathway: its functions and alterations in human cancer,” Apoptosis, vol. 9, no. 6, pp. 667–676, 2004. View at Publisher · View at Google Scholar · View at Scopus
  232. Z. X. Qiu, S. Zhao, L. Li, and W. M. Li, “Loss of expression of PTEN is associated with worse prognosis in patients with cancer,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 11, pp. 4691–4698, 2015. View at Google Scholar
  233. X.-L. Chen, J.-P. Fu, J. Shi, P. Wan, H. Cao, and Z.-M. Tang, “CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway,” Molecular Medicine Reports, vol. 12, no. 6, pp. 8229–8236, 2015. View at Publisher · View at Google Scholar
  234. A. Villanueva, C. Alsinet, K. Yanger et al., “Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice,” Gastroenterology, vol. 143, no. 6, pp. 1660.e7–1669.e7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  235. R. Ghasemi, S. H. Ghaffari, M. Momeny et al., “Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells,” Nutrition and Cancer, vol. 65, no. 4, pp. 590–599, 2013. View at Publisher · View at Google Scholar · View at Scopus
  236. O. Kucera, V. Mezera, A. Moravcova et al., “In vitro toxicity of epigallocatechin gallate in rat liver mitochondria and hepatocytes,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 476180, 10 pages, 2015. View at Publisher · View at Google Scholar
  237. D. Wang, Y. Wang, X. Wan, C. S. Yang, and J. Zhang, “Green tea polyphenol (−)-epigallocatechin-3-gallate triggered hepatotoxicity in mice: responses of major antioxidant enzymes and the Nrf2 rescue pathway,” Toxicology and Applied Pharmacology, vol. 283, no. 1, pp. 65–74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  238. M. Li, A. Shi, H. Pang et al., “Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects,” Journal of Ethnopharmacology, vol. 156, pp. 210–215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  239. A. B. Siegel, R. Narayan, R. Rodriguez et al., “A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma,” Integrative Cancer Therapies, vol. 13, no. 1, pp. 46–53, 2014. View at Publisher · View at Google Scholar · View at Scopus
  240. X. Yanyu, S. Yunmei, C. Zhipeng, and P. Qineng, “The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats,” International Journal of Pharmaceutics, vol. 307, no. 1, pp. 77–82, 2006. View at Publisher · View at Google Scholar · View at Scopus
  241. Y. Yun, Y. W. Cho, and K. Park, “Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery,” Advanced Drug Delivery Reviews, vol. 65, no. 6, pp. 822–832, 2013. View at Publisher · View at Google Scholar · View at Scopus
  242. R.-L. Duan, X. Sun, J. Liu, T. Gong, and Z.-R. Zhang, “Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility,” Acta Pharmacologica Sinica, vol. 32, no. 1, pp. 108–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  243. K. A. Khaled, Y. M. El-Sayed, and B. M. Al-Hadiya, “Disposition of the flavonoid quercetin in rats after single intravenous and oral doses,” Drug Development and Industrial Pharmacy, vol. 29, no. 4, pp. 397–403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  244. A. K. Mandal, D. Ghosh, S. Sarkar, A. Ghosh, S. Swarnakar, and N. Das, “Nanocapsulated quercetin downregulates rat hepatic MMP-13 and controls diethylnitrosamine-induced carcinoma,” Nanomedicine, vol. 9, no. 15, pp. 2323–2337, 2014. View at Publisher · View at Google Scholar · View at Scopus
  245. F. Dajas, “Life or death: neuroprotective and anticancer effects of quercetin,” Journal of Ethnopharmacology, vol. 143, no. 2, pp. 383–396, 2012. View at Publisher · View at Google Scholar
  246. P. Chen, M.-D. Hu, X.-F. Deng, and B. Li, “Genistein reinforces the inhibitory effect of cisplatin on liver cancer recurrence and metastasis after curative hepatectomy,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 2, pp. 759–764, 2013. View at Publisher · View at Google Scholar · View at Scopus